We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Nov 2023
  • Code : CMI5800
  • Pages :160
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

The global smallpox treatment market size was valued at US$ 67.5 million in 2023 and is expected to reach US$ 78 million by 2030, grow at a compound annual growth rate (CAGR) of 2.1% from 2023 to 2030. Increasing government funding and initiatives for research of antiviral medication is a key driver fueling the smallpox treatment market growth during the forecast period.

The smallpox treatment market is segmented by treatment type, route of administration, distribution channel, and region. Based on treatment type, the market is segmented into antiviral drugs, vaccination, and supportive care. Antivirals are the most widely used drugs for the treatment of smallpox. The market for antivirals is expected to grow during the forecast period. This is due to the increasing availability of new antiviral drugs for the treatment of smallpox.

Smallpox Treatment Market Regional Insights:

  • North America: North America is the largest market for smallpox treatments, accounting for a share of over 36.9% in 2023. North America holds the largest market share for smallpox treatment. This can be attributed to several factors, such as the high prevalence of smallpox in the region, substantial government funding for research and development, and a high level of awareness about the disease. The region's advanced healthcare infrastructure and strong pharmaceutical industry contribute to its dominance in the market.
  • Europe: Europe is the second-largest market for smallpox treatments, accounting for a share of over 28% in 2023 and Europe follows North America as the second largest market for smallpox treatment. Similar to North America, Europe experiences a significant prevalence of smallpox and benefits from considerable government funding for research and development initiatives. The region's well-established healthcare systems, presence of leading pharmaceutical companies, and emphasis on public health contribute to its substantial market share.
  • Asia Pacific: Asia Pacific is the fastest-growing market for smallpox treatments, accounting for a share of over 24% in 2023, and Asia Pacific is a region witnessing rapid growth in the smallpox treatment market. Factors such as a growing prevalence of smallpox, increasing government funding for research and development, and rising awareness about the disease contribute to the market expansion. The region's large population, especially in countries like China and India, plays a significant role in the increased demand for smallpox therapeutics.

Figure 1. Global Smallpox Treatment Market Share (%), by Region, 2023


To learn more about this report, request a free sample copy

Analyst View on Global Smallpox Treatment Market:

The global smallpox treatment market has strong growth potential over the forecast period, owing to the initiative by various government. North America is expected to continue dominating the smallpox treatment landscape due to large government stockpiles and research funding allocation in the region.

Moreover, increasing research and development (R&D) investments from key market players in Asia Pacific could see the region emerge as the fastest growing market. China, India, and Japan are prioritizing new drug development as their biotechnology industries are advancing. Several new therapeutic candidates are in preclinical and clinical trials, targeting both post-exposure prophylaxis and the treatment of symptomatic smallpox.

Smallpox Treatment Market Drivers:

  • Government Funding and Initiatives: Government funding plays a crucial role in driving the smallpox treatment market. Governments allocate funds for research and development activities, including the development of new therapeutics and vaccines, stockpiling of treatments, and strengthening healthcare infrastructure to effectively manage smallpox outbreaks. For instance, in August 2022, the U.S. Department of Health and Human Services announced that they will provide US$ 11 million to Bavarian Nordic A/S, a fully integrated biotechnology company, for the manufacturing of JYNNEOS, a vaccine used to prevent smallpox and monkeypox.
  • Awareness and Education: Awareness about smallpox among healthcare professionals, policymakers, and the general population is vital for the growth of the treatment market. Increased awareness leads to early detection, prompt treatment, and preventive measures, thereby driving the demand for smallpox treatment options.
  • Rising Geriatric Population: The global elderly population, aged 65 years and older, has been rising significantly and this rising geriatric population is a major driver for the growth of the global smallpox treatment market. Elderly people are more susceptible to various diseases and health conditions. Older individuals tend to have lower immunity and are more susceptible to viruses.

Smallpox Treatment Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 67.5 Mn
Historical Data for: 2018 to 2022 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 2.1% 2030 Value Projection: US$ 78 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil,  Mexico, Argentina, and Rest of LATAM
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East:  GCC, Israel, Rest of Middle East
  • Africa:  North Africa, Central Africa and South Africa
Segments covered:
  • By Treatment Type: Antiviral Drugs, Vaccination, Supportive Care
  • By Route of Administration: Oral, Injectable, Others (Topical, etc.)
  • By Distribution Channel: Hospitals (Public, Private), Retail Pharmacies, Online Pharmacies
Companies covered:

SIGA Technologies, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Pfizer Inc., Bharat Biotech International Ltd. and Chimerix, Inc.

Growth Drivers:
  • Increasing government funding and initiatives for research of antiviral medication
  • Awareness and education about smallpox
  • Rising geriatric population
Restraints & Challenges:
  • Eradication of Smallpox
  • Regulatory Hurdles
  • Potential side effects of treatments

Smallpox Treatment Market Opportunities:

  • Vaccine Development and Innovation: While smallpox has been eradicated, there is still a need for ongoing research and development of new and improved vaccines. Opportunities exist for the development of safer, more effective, and easier-to-administer vaccines. Advancements in vaccine technology, such as the use of novel adjuvants or alternative delivery methods, can improve vaccine efficacy and enhance immunization strategies.
  • Strengthening Healthcare Infrastructure: Opportunities exist to strengthen healthcare infrastructure, particularly in regions with limited resources or vulnerable populations. This includes enhancing laboratory capabilities for rapid diagnosis, improving surveillance and monitoring systems, investing in research and development for smallpox treatment options and establishing effective healthcare delivery systems to ensure timely and appropriate treatment for smallpox cases.
  • Public Health Awareness and Education: Increasing public awareness about smallpox, its prevention, and available treatment options can have a significant impact on disease control and prevention. Opportunities exist to develop comprehensive public health campaigns that educate the public, healthcare professionals, and policymakers about smallpox, its risks, and the importance of vaccination and early treatment.

Smallpox Treatment Market Trends:

  • Vaccine Stockpiling and Preparedness: Governments and international organizations continue to prioritize smallpox vaccine stockpiling and preparedness efforts. This trend involves maintaining an adequate supply of smallpox vaccines and related products to respond swiftly to potential outbreaks or bioterrorism threats.
  • Focus on precision and personalized medicine: The growing focus on precision and personalized medicine is having a significant influence on the global smallpox treatment market. With advancements in genetic research and diagnostics, doctors now have a more nuanced understanding of how individual patients may respond differently to different treatment options based on their unique genetic profile and medical history. This trend towards tailored, patient-specific treatment is also expected to act as a lucrative growth opportunity for the global smallpox treatment market growth.
  • Digital Solutions and Data Management: The integration of digital solutions and data management systems in smallpox treatment is gaining prominence. This trend includes the use of electronic medical records, data analytics, and real-time monitoring systems to enhance surveillance, track vaccination coverage, and facilitate prompt response during potential outbreaks.
  • Emerging Technologies: Advancements in biotechnology and emerging technologies, such as gene editing, synthetic biology, and nanotechnology, hold potential for revolutionizing smallpox treatment. These technologies may contribute to the development of innovative vaccine platforms, antiviral therapies, and diagnostic tools for improved management of smallpox.

Smallpox Treatment Market Restraints:

  • Eradication of Smallpox: The eradication of smallpox is a significant restraint in the smallpox treatment market. As smallpox no longer exists in the world, there is no ongoing transmission or active cases of the disease, resulting in a limited market for smallpox treatments.
  • Regulatory Hurdles: Regulatory hurdles pose challenges in the development and approval of smallpox treatments. The stringent regulatory requirements for safety and efficacy evaluation, even in emergency situations, can delay the availability of new treatments or repurposed drugs for smallpox.
  • Potential Side Effects: Smallpox treatments, including vaccines and antiviral therapeutics, can have potential side effects and adverse reactions. Ensuring safety and minimizing risks associated with these treatments is a critical concern, particularly in the absence of active smallpox cases where the risk-benefit balance needs careful evaluation. For instance, Tecovirimat (Tpoxx), which is manufactured by SIGA Technologies, a U.S.-based pharmaceutical company, has shown efficacy in treating smallpox, however, it also has side effects such as headache, nausea, diarrhea, dizziness, fatigue, rash and elevated liver enzymes.

Recent Developments

New product Approval

  • In June 2021, Chimerix Inc., a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted TEMBEXA (brincidofovir) tablets and oral suspension approval for the treatment of smallpox in adult and pediatric patients.
  •  In May 2022, GA Technologies, a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its intravenous (IV) formulation of TPOXX for the treatment of smallpox.


  • In September 2022, Emergent BioSolutions Inc., a U.S.-based multinational specialty biopharmaceutical company, announced that they had acquired exclusive worldwide rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox, from Chimerix Inc., a U.S.-based biopharmaceutical company.

Figure 2. Global Smallpox Treatment Market Share (%), by Treatment Type, 2023


To learn more about this report, request a free sample copy

Top companies in Smallpox Treatment Market

  • SIGA Technologies, Inc.
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Sanofi
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bharat Biotech International Ltd.
  • Chimerix, Inc.

Definition: Smallpox treatment refers to the medical interventions and therapies aimed at managing and combating smallpox, a highly contagious and potentially deadly viral infection caused by the variola virus. The treatment approaches may include the administration of antiviral drugs, vaccination with smallpox vaccines, and supportive care to alleviate symptoms and prevent complications. The goal of smallpox treatment is to control the spread of the disease, minimize the severity of symptoms, and improve patient outcomes.

Frequently Asked Questions

The key factors hampering the growth of the smallpox treatment market include the eradication of smallpox, regulatory hurdles, and potential side effects of treatments.

The major factors driving the market growth include the increasing government funding and initiatives for research of antiviral medication, awareness and education about smallpox, and a rising geriatric population.

The leading treatment type segment in the market includes antiviral drugs, which are widely used for the treatment of smallpox.

Some of the major players operating in the market include SIGA Technologies, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Pfizer Inc., Bharat Biotech International Ltd. and Chimerix, Inc.

North America is expected to lead the market, followed by Europe and Asia Pacific.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo